ダルベポエチンアルファ（アラネスプ）の世界市場レポート 2024年

ダルベポエチンアルファ（アラネスプ）の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には4.8%の年間複合成長率（CAGR）で71億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、ヘルスケア償還政策の影響、意識の高まりと教育的取り組み、継続的なヘルスケアインフラの開発、腎臓ケアの需要の高まり、高齢者人口の増加など、いくつかの重要な要因によるものと考えられます。これらの要素は、貧血に関する治療の拡大に大きく貢献すると期待されています。この期間に予測される主な動向には、世界市場の拡大、デジタルヘルス技術のヘルスケア実践への統合、個別化された治療アプローチの採用、バイオシミラーの利用増加、長時間作用型製剤の開発などが含まれます。これらの動向は、貧血の治療とヘルスケア提供の将来の情勢を形成し、患者のケアと管理の進歩と改善を促進しようとしています。

慢性疾患の有病率の増加により、ダルベポエチンアルファ市場の成長が今後も促進されると予想されます。慢性疾患とは、3か月以上続き、時間の経過とともに悪化する可能性がある病気の一種です。ダルベポエチンアルファは、さまざまな慢性疾患の治療や、がんにおける化学療法誘発性の貧血を逆転させるために使用されます。たとえば、米国に本拠を置く機関である国立医学図書館によると、2023年1月には、少なくとも1つの慢性疾患を有する米国の50歳以上の人の数は、2020年の7,152万2,000人から、2050年には1億4,266万人へ、99.5%増加すると予想されています。したがって、慢性疾患の有病率の増加がダルベポエチンアルファ市場の成長を推進しています。

糖尿病の有病率の上昇により、ダルベポエチンアルファ市場の成長が今後も促進されると予想されます。糖尿病は、血糖値の上昇を引き起こす長期にわたる代謝性疾患を指します。この状態は時間が経つと、心臓、血管、目、腎臓、神経、その他の臓器に重大な障害を引き起こします。ダルベポエチンアルファは、糖尿病に伴う貧血に対処し、赤血球の産生を促進し、全体的な生活の質を改善することにより、糖尿病患者において重要な役割を果たします。たとえば、ベルギーに本拠を置く糖尿病連盟である国際糖尿病連盟によると、2022年6月、糖尿病の有病率は世界全体で10.5％に増加し、半数以上（44.7％）の人がまだ診断されていないとのこと。 IDFの予測によると、2045年までに成人 7億8,300万人、つまり8人に1人が糖尿病になると予想されています。これは46%の増加に相当し、同時期の人口増加予測（20%）の2倍以上となります。したがって、糖尿病の有病率の上昇がダルベポエチンアルファ市場の成長を推進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のダルベポエチンアルファ（アラネスプ）市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界のダルベポエチンアルファ（アラネスプ）の市場規模実績と成長、2018年～2023年
• 世界のダルベポエチンアルファ（アラネスプ）の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のダルベポエチンアルファ（アラネスプ）市場、タイプ別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• エポジェン
• プロクリット
• アラネスプ
• その他のタイプ
• 世界のダルベポエチンアルファ（アラネスプ）市場、流通チャネル別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のダルベポエチンアルファ（アラネスプ）市場、用途別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 慢性腎臓病患者
• がん患者
• その他の用途

第7章 地域および国の分析

• 世界のダルベポエチンアルファ（アラネスプ）市場、地域別、実績および予測、2018年～2023年、2023年～2028年、2033年
• 世界のダルベポエチンアルファ（アラネスプ）市場、国別、実績および予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ダルベポエティンアルファ（アラネスプ）市場の競合情勢
• ダルベポエチンアルファ（アラネスプ）市場の企業プロファイル
  • Johnson &Johnson
  • Amgen Inc.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Serum Institute of India Pvt. Ltd.

第31章 その他の主要・革新的企業

• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Biocon Ltd.
• Reliance Life Sciences
• Torrent Pharmaceuticals Ltd.
• 3SBio Inc.
• Cadila Healthcare Ltd.
• Dong-A ST Co. Ltd.
• Chong Kun Dang Holdings
• Hetero Drugs Ltd.
• Intas Pharmaceuticals Ltd.
• Avesthagen Pharma
• Stada Arzneimittel AG
• Ranbaxy Laboratories Ltd.
• Sandoz International GmbH

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Darbepoetin alfa (Aranesp) is a medication utilized in treating anemia associated with chemotherapy and chronic kidney disease by stimulating the production of red blood cells in the bone marrow.

The primary variations of darbepoetin alfa (Aranesp) include Epogen, Procrit, Aranesp, and other related forms. Epogen is a synthetic protein designed to boost the body's red blood cell production and is specifically employed to address anemia, characterized by a deficiency of red blood cells. These medications are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and find application in treating patients with chronic kidney disease, individuals with cancer, and other relevant medical conditions.

The darbepoetin alfa market research report is one of a series of new reports from The Business Research Company that provides darbepoetin alfa market statistics, including darbepoetin alfa industry global market size, regional shares, competitors with darbepoetin alfa market share, detailed darbepoetin alfa market segments, market trends, and opportunities, and any further data you may need to thrive in the darbepoetin alfa industry. This darbepoetin alfa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.56 billion in 2023 to $5.88 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed during the historical period can be attributed to several factors, including advancements in the treatment of anemia, increased demand for erythropoiesis-stimulating agents (ESAs), innovations in biopharmaceuticals, greater clinical acceptance of these treatments, and the consequent improvement in patient outcomes. These elements collectively contributed to the expansion and development of therapies aimed at addressing anemia-related conditions.

The darbepoetin alfa (aranesp) market size is expected to see steady growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to several key factors, including the impact of healthcare reimbursement policies, heightened awareness and educational initiatives, ongoing development of healthcare infrastructure, rising demands for renal care, and the increasing population of older adults. These elements are expected to significantly contribute to the expansion of treatments related to anemia. Major trends projected for this period encompass the global market expansion, integration of digital health technologies into healthcare practices, the adoption of personalized treatment approaches, the increased utilization of biosimilars, and the development of long-acting formulations. These trends are poised to shape the future landscape of anemia treatments and healthcare delivery, fostering advancements and improvements in patient care and management.

The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Darbepoetin alfa is used to treat various chronic diseases, to reverse chemotherapy-induced anemia in cancer. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

The rising prevalence of diabetes is expected to propel the growth of the darbepoetin alfa market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. Over time, this condition causes major harm to the heart, blood vessels, eyes, kidneys, nerves, and other organs. Darbepoetin alfa plays a crucial role in diabetes patients by addressing the anemia associated with the condition, promoting red blood cell production, and improving overall quality of life. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed. According to IDF predictions, 783 million adults, or one in eight people, will have diabetes by 2045. This would represent a 46% rise, more than double the projected population growth for the same period (20%). Therefore, the rising prevalence of diabetes is driving the growth of the darbepoetin alfa market.

Product innovation stands out as a significant trend gaining momentum in the darbepoetin alfa market, with major companies strategically adopting new technologies to secure their market positions. GlaxoSmithKline Ltd., a UK-based pharmaceutical and biotechnology company, exemplifies this trend by introducing Jesduvroq (daprodustat) in February 2023. The US Food and Drug Administration (FDA), a US-based government agency, approved Jesduvroq as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the once-daily treatment of anemia induced by chronic kidney disease (CKD) in individuals on dialysis for at least four months.

Major companies in the darbepoetin alfa market are intensifying their focus on introducing novel medications to gain a competitive advantage. A case in point is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to address anemia associated with chronic kidney disease. Akebia Therapeutics, a US-based biotechnology company, obtained approval from Australia's Therapeutic Goods Administration (TGA) for Vafseo in September 2023. This approval extends to 36 countries, including Taiwan, and is based on the positive outcomes from the global Phase 3 clinical program demonstrating the efficacy of vadadustat in treating anemia due to CKD in adults on chronic maintenance dialysis. The commitment to introducing innovative products reflects the dedication of major companies in advancing solutions within the darbepoetin alfa market.

In July 2021, Chong Kun Dang Pharmaceutical, a leading pharmaceutical company based in South Korea, forged a partnership with Menagen Pharmaceutical Industries to distribute a darbepoetin alfa biosimilar across the Middle Eastern market, particularly targeting the Gulf Cooperation Council (GCC) nations. This collaboration encompasses technology transfer, manufacturing, and the commercialization of the darbepoetin alfa biosimilar. Menagen Pharmaceutical Industries, headquartered in Oman, specializes in the development and manufacturing of various specialized therapeutic products.

Major companies operating in the darbepoetin alfa (aranesp) market report are Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Iko Pharmaceutical Co. Ltd., Menagen Pharmaceutical Industries, Kyowa Kirin Co. Ltd., Polifarma S.p.A.

North America was the largest region in the darbepoetin alfa market in 2023. The regions covered in the darbepoetin alfa (aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the darbepoetin alfa (aranesp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The darbepoetin alfa market consists of sales of Aranesp sure click, Aranesp albumin free, and Aranesp sing eject. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Darbepoetin Alfa (Aranesp) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on darbepoetin alfa (aranesp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for darbepoetin alfa (aranesp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The darbepoetin alfa (aranesp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Epogen; Procrit; Aranesp; Other Types
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Application: Patients with Chronic Kidney Disease; Patients with Cancer; Other Applications
• Companies Mentioned: Johnson & Johnson; Amgen Inc.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Serum Institute of India Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Darbepoetin Alfa (Aranesp) Market Characteristics

3. Darbepoetin Alfa (Aranesp) Market Trends And Strategies

4. Darbepoetin Alfa (Aranesp) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Darbepoetin Alfa (Aranesp) Market Size and Growth

• 5.1. Global Darbepoetin Alfa (Aranesp) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Darbepoetin Alfa (Aranesp) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Darbepoetin Alfa (Aranesp) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Darbepoetin Alfa (Aranesp) Market Segmentation

• 6.1. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Epogen
• Procrit
• Aranesp
• Other Types
• 6.2. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Patients with Chronic Kidney Disease
• Patients with Cancer
• Other Applications

7. Darbepoetin Alfa (Aranesp) Market Regional And Country Analysis

• 7.1. Global Darbepoetin Alfa (Aranesp) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Darbepoetin Alfa (Aranesp) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Darbepoetin Alfa (Aranesp) Market

• 8.1. Asia-Pacific Darbepoetin Alfa (Aranesp) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Darbepoetin Alfa (Aranesp) Market

• 9.1. China Darbepoetin Alfa (Aranesp) Market Overview
• 9.2. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Darbepoetin Alfa (Aranesp) Market

• 10.1. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Darbepoetin Alfa (Aranesp) Market

• 11.1. Japan Darbepoetin Alfa (Aranesp) Market Overview
• 11.2. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Darbepoetin Alfa (Aranesp) Market

• 12.1. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Darbepoetin Alfa (Aranesp) Market

• 13.1. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Darbepoetin Alfa (Aranesp) Market

• 14.1. South Korea Darbepoetin Alfa (Aranesp) Market Overview
• 14.2. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Darbepoetin Alfa (Aranesp) Market

• 15.1. Western Europe Darbepoetin Alfa (Aranesp) Market Overview
• 15.2. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Darbepoetin Alfa (Aranesp) Market

• 16.1. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Darbepoetin Alfa (Aranesp) Market

• 17.1. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Darbepoetin Alfa (Aranesp) Market

• 18.1. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Darbepoetin Alfa (Aranesp) Market

• 19.1. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Darbepoetin Alfa (Aranesp) Market

• 20.1. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Darbepoetin Alfa (Aranesp) Market

• 21.1. Eastern Europe Darbepoetin Alfa (Aranesp) Market Overview
• 21.2. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Darbepoetin Alfa (Aranesp) Market

• 22.1. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Darbepoetin Alfa (Aranesp) Market

• 23.1. North America Darbepoetin Alfa (Aranesp) Market Overview
• 23.2. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Darbepoetin Alfa (Aranesp) Market

• 24.1. USA Darbepoetin Alfa (Aranesp) Market Overview
• 24.2. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Darbepoetin Alfa (Aranesp) Market

• 25.1. Canada Darbepoetin Alfa (Aranesp) Market Overview
• 25.2. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Darbepoetin Alfa (Aranesp) Market

• 26.1. South America Darbepoetin Alfa (Aranesp) Market Overview
• 26.2. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Darbepoetin Alfa (Aranesp) Market

• 27.1. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Darbepoetin Alfa (Aranesp) Market

• 28.1. Middle East Darbepoetin Alfa (Aranesp) Market Overview
• 28.2. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Darbepoetin Alfa (Aranesp) Market

• 29.1. Africa Darbepoetin Alfa (Aranesp) Market Overview
• 29.2. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Darbepoetin Alfa (Aranesp) Market Competitive Landscape And Company Profiles

• 30.1. Darbepoetin Alfa (Aranesp) Market Competitive Landscape
• 30.2. Darbepoetin Alfa (Aranesp) Market Company Profiles
  • 30.2.1. Johnson & Johnson
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Amgen Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Mylan N.V.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Teva Pharmaceutical Industries Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Serum Institute of India Pvt. Ltd.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Darbepoetin Alfa (Aranesp) Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories Ltd.
• 31.2. Cipla Ltd.
• 31.3. Biocon Ltd.
• 31.4. Reliance Life Sciences
• 31.5. Torrent Pharmaceuticals Ltd.
• 31.6. 3SBio Inc.
• 31.7. Cadila Healthcare Ltd.
• 31.8. Dong-A ST Co. Ltd.
• 31.9. Chong Kun Dang Holdings
• 31.10. Hetero Drugs Ltd.
• 31.11. Intas Pharmaceuticals Ltd.
• 31.12. Avesthagen Pharma
• 31.13. Stada Arzneimittel AG
• 31.14. Ranbaxy Laboratories Ltd.
• 31.15. Sandoz International GmbH

32. Global Darbepoetin Alfa (Aranesp) Market Competitive Benchmarking

33. Global Darbepoetin Alfa (Aranesp) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Darbepoetin Alfa (Aranesp) Market

35. Darbepoetin Alfa (Aranesp) Market Future Outlook and Potential Analysis

• 35.1 Darbepoetin Alfa (Aranesp) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Darbepoetin Alfa (Aranesp) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Darbepoetin Alfa (Aranesp) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer